



Dedicated to you

## Financial Statements

**Ceylon Hospitals PLC**

*For the 1st Quarter ended 30th June 2021*

**Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	<b>Group</b>		<b>Company</b>	
	<b>03 Months</b>	03 Months	<b>03 Months</b>	03 Months
	<b>Ended</b>	Ended	<b>Ended</b>	Ended
	<b>30/06/2021</b>	30/06/2020	<b>30/06/2021</b>	30/06/2020
	<b>Rs. '000</b>	Rs. '000	<b>Rs. '000</b>	Rs. '000
Revenue	<b>1,880,131</b>	897,280	<b>1,259,665</b>	532,544
Cost of Sales	<b>(734,546)</b>	(318,439)	<b>(516,694)</b>	(189,373)
Gross Profit	<b>1,145,586</b>	578,842	<b>742,972</b>	343,172
Other Operating Income	<b>8,614</b>	4,970	<b>4,692</b>	4,082
<b>Overheads</b>				
Administrative Expenses	<b>(699,633)</b>	(467,569)	<b>(501,476)</b>	(304,864)
Other Operating Expenses	<b>(162,320)</b>	(104,609)	<b>(109,944)</b>	(63,938)
Finance Cost	<b>(23,872)</b>	(26,871)	<b>(22,767)</b>	(23,740)
Finance Income	<b>19,642</b>	9,781	<b>152,507</b>	129
	<b>(866,183)</b>	(589,268)	<b>(481,681)</b>	(392,413)
Gain on Bargain Purchase	<b>12,002</b>	-	-	-
Share of Profit of an Equity Accounted Investee	<b>13,263</b>	2,566	-	-
Profit Before Taxation	<b>313,282</b>	(2,891)	<b>265,983</b>	(45,159)
Taxation	<b>(83,542)</b>	(14,163)	<b>(41,766)</b>	(3,392)
Net Profit after Taxation	<b>229,740</b>	(17,054)	<b>224,217</b>	(48,552)
<b>Other Comprehensive Income</b>				
<b>Items will not be reclassified to profit or loss</b>				
Net Change in Fair Value on Equity Investments at FVOCI	<b>56</b>	748	<b>56</b>	56
Other Comprehensive Income for the Year	<b>56</b>	748	<b>56</b>	56
<b>Total Comprehensive Income for the Year</b>	<b>229,796</b>	(16,307)	<b>224,273</b>	(48,496)
Profit Attributable to:				
Equity Holders of the Parent	<b>193,691</b>	(20,637)	<b>224,217</b>	(48,552)
Non-Controlling Interest	<b>36,049</b>	3,583	-	-
	<b>229,740</b>	(17,054)	<b>224,217</b>	(48,552)
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent	<b>193,747</b>	(20,020)	<b>224,273</b>	(48,496)
Non-Controlling Interest	<b>36,049</b>	3,713	-	-
	<b>229,796</b>	(16,307)	<b>224,273</b>	(48,496)
<b>Earnings per Share - Basic</b>	<b>5.72</b>	(0.61)	<b>6.62</b>	(1.43)

The above figures are provisional and subject to audit.

**Consolidated Statement of Financial Position**

GROUP COMPANY		GROUP		COMPANY		
Audited	Audited	Unaudited	Audited	Unaudited	Audited	
As at	As at	As at	As at	As at	As at	
31/03/2021	31/03/2021	30/06/2021	30/06/2020	30/06/2021	30/06/2020	
Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	
ASSETS						
Non-Current Assets						
7,714,638	5,083,367	Property, Plant and Equipment	7,796,767	7,649,295	5,166,959	4,976,678
214,544	214,544	Right of Use Assets	206,644	194,690	206,644	194,690
-	1,457,591	Investments in Subsidiary	-	-	1,457,821	1,457,591
109,374	230	Investment in Equity Accounted Investee	-	8,063	-	230
165,973	66,910	Other Financial Assets	216,607	101,778	67,350	62,833
990	-	Prepaid Rent	853	1,065	-	-
8,205,519	6,822,642		8,220,870	7,954,891	6,898,773	6,692,022
Current Assets						
535,877	450,475	Inventories	632,693	413,531	505,034	330,762
237,950	157,209	Trade and Other Receivables	368,957	311,115	209,465	171,707
155,456	121,194	Prepayments	204,290	242,756	167,610	221,605
2,418	82,769	Amount Due from Related Parties	370	59,966	82,717	495,690
1,106,141	123,176	Other Financial Assets	824,417	567,919	130,407	88,030
-	-	Tax Refund Due	-	40,506	-	18,222
640,115	225,211	Cash and Cash Equivalents	811,655	304,236	303,714	61,679
2,677,958	1,160,034		2,842,382	1,940,029	1,398,946	1,387,694
10,883,477	7,982,676	Total Assets	11,063,252	9,894,920	8,297,720	8,079,716
EQUITY AND LIABILITIES						
Equity Attributable to Equity holders of the parent						
916,366	916,366	Stated Capital	916,366	916,366	916,366	916,366
2,691,662	2,134,544	Revaluation Reserve	2,691,662	2,483,785	2,134,544	1,931,063
68,436	128	Fair Value Reserve	68,492	66,539	184	56
2,951,439	1,986,400	Revenue Reserves	3,036,737	2,419,116	2,102,224	1,539,513
6,627,903	5,037,438		6,713,258	5,885,807	5,153,318	4,386,998
592,626	-	Non-Controlling Interests	727,986	592,223	-	-
7,220,530	5,037,438	Total Equity	7,441,244	6,478,029	5,153,318	4,386,998
Non-Current Liabilities						
823,144	784,444	Interest Bearing Loans and Borrowings	879,217	640,685	818,299	588,185
-	33,261	Deferred Revenue	-	-	32,925	34,603
242,882	217,078	Retirement Benefit Obligations	243,703	270,422	218,148	239,130
642,694	440,809	Deferred Tax Liabilities	646,650	915,540	440,809	703,190
1,708,719	1,475,592		1,769,569	1,826,647	1,510,181	1,565,107
Current Liabilities						
221,737	72,894	Bank Overdraft	304,588	631,731	246,890	581,946
829,176	793,416	Interest Bearing Loans and Borrowings	562,734	331,360	525,141	318,860
671,130	384,716	Trade and Other Payables	918,472	600,075	583,099	329,837
55,191	41,894	Taxation Payable	54,795	11,080	35,567	-
176,994	176,727	Amount Due to Related Parties	11,850	15,997	243,523	896,968
1,954,228	1,469,647		1,852,439	1,590,243	1,634,221	2,127,611
10,883,477	7,982,676	Total Equity and Liabilities	11,063,252	9,894,920	8,297,720	8,079,716

The above figures are provisional and subject to audit.

Snd.  
**H M D Herat Gunaratne**  
 Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.  
 Signed for and on behalf of the Board by,

Snd.  
**A E Tudawe**  
 Chairman

Snd.  
**U D Tudawe**  
 Director

**CEYLON HOSPITALS PLC**  
**STATEMENT OF CHANGES IN EQUITY**

**Group**

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Accumulated Profits Rs.	Total Rs.	Non-Controlling Interest Rs.	Total Rs.
<b>Balance as at 31st March 2020</b>	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Period	-	-	-	560,349	560,349	39,910	600,259
<b>Other Comprehensive Income</b>							
Deferred Tax Effect on Revaluation Gain	-	207,877	-	-	207,877	752	208,629
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	32,865	32,865	370	33,235
Deferred Tax Charge on actuarial Loss on Gratuity Valuation	-	-	-	(7,007)	(7,007)	(610)	(7,618)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	2,514	-	2,514	554	3,068
<b>Total Comprehensive Income for the Period</b>	-	207,877	2,514	586,206	796,597	40,975	837,572
<b>Transactions with Owners in their capacity as Owners</b>							
Share of additional capital attributable to NCI	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)	(37,859)	(112,379)
	-	-	-	(74,520)	(74,520)	(36,109)	(110,629)
<b>Balance as at 31st March 2021</b>	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,530
Net Profit for the Period	-	-	-	193,691	193,691	36,049	229,740
<b>Other Comprehensive Income</b>							
-Value through other comprehensive income	-	-	56	-	-	-	56
<b>Total Comprehensive Income for the Period</b>	-	-	56	193,691	193,691	36,049	229,796
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	126,444	126,444
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(27,133)	(135,526)
	-	-	-	(108,393)	(108,393)	99,311	(9,082)
<b>Balance as at 30th June 2021</b>	916,366	2,691,662	68,492	3,036,737	6,713,202	727,986	7,441,244

**Company**

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Accumulated Profits Rs.	Total Rs.
<b>Balance as at 31st March 2020</b>	916,366	1,931,063	-	1,588,064	4,435,493
Net Profit for the Period	-	-	-	446,118	446,118
<b>Other Comprehensive Income</b>					
Deferred Tax Effect on Revaluation Gain	-	203,481	-	-	203,481
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	31,090	31,090
Deferred Tax Effect on Gratuity Valuation	-	-	-	(4,353)	(4,353)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	128.00	-	128
<b>Total Comprehensive Income for the Period</b>	-	203,481	128	472,855	676,464
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)
	-	-	-	(74,520)	(74,520)
<b>Balance as at 31st March 2021</b>	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit/(Loss) for the period	-	-	-	224,217	224,217
<b>Other Comprehensive Income</b>					
Net Profit on equity instruments designnated at fair-	-	-	-	-	-
-Value through other comprehensive income	-	-	56	-	56
<b>Total Comprehensive Income for the Period</b>	-	-	56	224,217	224,273
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	-	-	-	(108,393)	(108,393)
<b>Balance as at 30th June 2021</b>	916,366	2,134,544	184	2,102,224	5,153,318

**Consolidated Statement of Changes in Equity**  
**For the period ended 30th June 2020**

**Group**

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Accumulated Profits Rs.	Total Rs.	NCI Rs.	Total Rs.
<b>Balance as at 31st March 2019</b>	916,366	1,986,853	69,939	2,169,904	5,143,062	564,744	5,707,805
Net Profit for the Period	-	-	-	403,274	403,274	63,819	467,093
<b>Other Comprehensive Income</b>							
Deferred Tax Effect on Revaluation Gain	-	(186,990)	-	-	(186,990)	(4,091)	(191,080)
Deferred Tax Effect on Gratuity Valuation	-	-	-	4,149	4,149	98	4,247
Net Gain/ (Loss) on Gratuity Valuation	-	-	-	(15,632)	(15,632)	(490)	(16,122)
Net Gain/ (Loss) on Land and Building Valuation	-	683,922	-	-	683,922	26,413	710,335
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(4,017)	-	(4,017)	(920)	(4,937)
<b>Total Comprehensive Income for the Period</b>	-	<b>496,933</b>	<b>(4,017)</b>	<b>391,791</b>	<b>884,706</b>	<b>84,830</b>	<b>969,536</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Dividend Paid - Ordinary Shares	-	-	-	(121,942)	(121,942)	(61,814)	(183,756)
	-	-	-	<b>(121,942)</b>	<b>(121,942)</b>	<b>(61,814)</b>	<b>(183,756)</b>
<b>Balance as at 31st March 2020</b>	<b>916,366</b>	<b>2,483,785</b>	<b>65,922</b>	<b>2,439,753</b>	<b>5,905,826</b>	<b>587,760</b>	<b>6,493,586</b>
Net Profit for the Period	-	-	-	(20,637)	(20,637)	3,583	(17,054)
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVOCI	-	-	617	-	617	130	748
<b>Total Comprehensive Income for the Period</b>	-	-	<b>617</b>	<b>(20,637)</b>	<b>(20,020)</b>	<b>3,713</b>	<b>(16,307)</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	750	750
	-	-	-	-	-	<b>750</b>	<b>750</b>
<b>Balance as at 30th June 2020</b>	<b>916,366</b>	<b>2,483,785</b>	<b>66,539</b>	<b>2,419,116</b>	<b>5,885,807</b>	<b>592,223</b>	<b>6,478,029</b>

**Company**

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Accumulated Profits Rs.	Total Rs.
<b>Balance as at 31st March 2019</b>	916,366	1,564,589	56	1,502,005	3,983,016
Net Profit for the Period	-	-	-	217,404	217,404
<b>Other Comprehensive Income</b>					
Deferred Tax Effect on Revaluation Gain	-	(163,081)	-	-	(163,081)
Deferred Tax Effect on Gratuity Valuation	-	-	-	3,657	3,657
Net Gain/ (Loss) on Gratuity Valuation	-	-	-	(13,060)	(13,060)
Net Gain/ (Loss) on Land and Building Valuation	-	529,555	-	-	529,555
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(56.00)	-	(56)
<b>Total Comprehensive Income for the Period</b>	-	<b>366,474</b>	<b>(56)</b>	<b>208,001</b>	<b>574,419</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(121,942)	(121,942)
	-	-	-	(121,942)	(121,942)
<b>Balance as at 31st March 2020</b>	<b>916,366</b>	<b>1,931,063</b>	-	<b>1,588,064</b>	<b>4,435,493</b>
Net Profit/(Loss) for the period	-	-	-	(48,552)	(48,552)
<b>Other Comprehensive Income</b>					
Net Change in Fair Value on Equity Investments at FVOCI	-	-	56	-	56
<b>Total Comprehensive Income for the Period</b>	-	-	<b>56</b>	<b>(48,552)</b>	<b>(48,496)</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	-	-
	-	-	-	-	-
<b>Balance as at 30th June 2020</b>	<b>916,366</b>	<b>1,931,063</b>	<b>56</b>	<b>1,539,513</b>	<b>4,386,998</b>

## Statement of Cash Flows

Group Audited 12 Months Ended 31/03/2021 Rs '000	Company Audited 12 Months Ended 31/03/2021 Rs '000		Group Unaudited 3 Months Ended 30/06/2021 Rs '000	Audited 3 Months Ended 30/06/2020 Rs '000	Company Unaudited 3 Months Ended 30/06/2021 Rs '000	Audited 3 Months Ended 30/06/2020 Rs '000
<b>Cash Flows from/ (Used in) Operating Activities</b>						
696,339	453,632	Net Profit Before Income Tax Expenses	313,282	(2,891)	265,983	(45,159)
		Adjustments for :		-		-
6,705	5,550	Inventory Write-off/(Net)	9,810	381	9,384	404
11,335	3,545	Bad Debts Write-off	300	1,230	300	230
354,740	190,061	Depreciation Charge for the Year	80,458	86,479	43,801	40,479
101,892	101,892	Amortisation of Right to use assets	25,991	26,128	25,991	25,991
(50,308)	(216,541)	Finance Income	(19,642)	(9,781)	(152,507)	(129)
96,679	88,169	Finance Cost	23,872	26,871	22,767	23,740
100	(1,790)	Amortisation of Deferred Rent	137	25	(336)	(448)
(5,340)	(5,340)	(Profit)/ Loss on Disposal of Property, Plant and Equipment	-	375	-	375
5,412	128	(Increase)/ Decrease in Financial Instruments	347	748	56	56
(102,871)	-	Share of Profit of an Equity Accounted Investee	(13,263)	(2,566)	-	-
49,845	43,504	Provision for Defined Benefit Plans	9,530	9,900	8,100	8,100
1,164,528	662,809	Operating Profit before Working Capital Changes	430,821	136,898	223,539	53,639
(162,833)	(147,103)	(Increase)/Decrease in Inventories	(106,626)	(34,163)	(63,943)	(22,244)
80,106	42,131	(Increase)/Decrease in Trade and Other Receivables	(180,141)	(70,253)	(98,971)	(69,462)
160,669	92,447	Increase/(Decrease) in Trade and Other Payables	247,342	85,998	198,383	33,951
219,127	(324,683)	(Increase)/Decrease Related Party Dues	(163,096)	582	66,849	(17,361)
1,461,598	325,601	Cash Generated from Operations	228,300	119,062	325,857	(21,478)
(70,135)	(61,624)	Finance Cost Paid	(17,802)	(23,255)	(16,698)	(20,123)
(39,020)	(30,438)	Defined Benefit Plan Costs Paid	(8,709)	(4,769)	(7,030)	(4,072)
(87,932)	(15,946)	Income Tax Paid	(79,982)	(18,797)	(48,093)	(8,689)
1,264,511	217,593	Net Cash from Operating Activities	121,807	72,241	254,036	(54,362)
<b>Cash Flows from/ (used in) Investing Activities</b>						
(384,556)	(299,170)	Acquisition of Property, Plant and Equipment	(162,877)	(71,948)	(127,393)	(63,896)
(2,425)	(2,425)	Acquisition of Right to use assets	(4,645)	(4,645)	(4,509)	(4,509)
13,945	13,655	Proceeds from Sale of Property, Plant and Equipment	290	1,290	-	1,000
(444,441)	(40,159)	(Acquisition)/ Disposal of other Investments	353,573	161,326	(7,671)	(935)
50,308	216,541	Income from Investments	19,642	9,781	152,507	129
(767,169)	(111,558)	Net Cash Flows from/ (used in) Investing Activities	205,983	95,804	12,935	(68,210)
<b>Cash Flows from/ (used in) Financing Activities</b>						
915,630	890,630	Receipts from Interest Bearing Loans and Borrowings	105,015	60,542	72,025	60,542
(302,106)	(282,766)	Re-payments to Interest Bearing Loans and Borrowing	(304,402)	(91,543)	(295,462)	(87,743)
(116,569)	(116,569)	Lease Rent Payment	(30,634)	-	(30,634)	-
1,750	-	Proceeds from the Issue of Shares	-	750	-	-
		Non-Controlling Interest on Acquisition of Subsidiary	126,444	-	-	-
(112,379)	(74,520)	Dividends Paid	(135,526)	-	(108,393)	-
386,326	416,775	Net Cash Flows from/ (used in) Financing Activities	(239,102)	(30,251)	(362,464)	(27,201)
883,668	522,810	Net Increase/ (Decrease) in Cash and Cash Equivalents	88,688	137,794	(95,493)	(149,773)
(465,289)	(370,493)	Cash and Cash Equivalents at the Beginning of the Year	418,379	(465,289)	152,317	(370,493)
418,379	152,317	Cash and Cash Equivalents at the End of the Year	507,067	(327,495)	56,824	(520,267)
<b>Analysis of Cash and Cash Equivalents</b>						
(221,737)	(72,894)	Bank Overdraft	(304,588)	(631,731)	(246,890)	(581,946)
640,115	225,211	Cash in Hand and at Bank	811,655	304,236	303,714	61,679
418,379	152,317		507,067	(327,495)	56,824	(520,267)

**Explanatory Notes****01. CORPORATE INFORMATION**

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

**02. INTERIM CONDENSED FINANCIAL STATEMENTS**

The financial statements for the period ended 30 June 2021, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

**03. APPROVAL OF FINANCIAL STATEMENTS**

The interim condensed financial statements of the Group and the Company for the period ended 30 June 2021 were authorised for issue by the Board of Directors on 11 August 2021.

**04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES****4.1 Basis of preparation**

The interim financial statements for the period ended 30 June 2021 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 March 2021.

**4.2 Fair value measurement and related fair value disclosures**

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 30 June 2021 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

**4.3 COVID - 19 impact assessment**

The Company has been in continuous operation although at reduced level subject to guidelines set out by the Government of Sri Lanka (GOSL) during the COVID-19 pandemic confirming to the regulations and guidelines issued by the GOSL, Ministry of Health (MOH) and other allied authorities.

Although it is too early to make an assessment, the Company has seen a smooth transition with the resumption of business activities with a positive momentum. Given the volatile and evolving landscape, the Company will continue to monitor the impacts on its operations and proactively take measures to ensure the business continues as seamlessly as possible.

No circumstances have arisen since the Balance Sheet date, which would require adjustment or disclosure in the interim Financial Statements other than what is stated above.

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.

06. Related party transactions for the quarter ended 30 June 2021 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

**Related Party Transactions**  
**For the period ended 30 June 2021 In LKR '000s**

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Durdans Management Services Ltd	Ultimate Parent	Management fee	Recurrent	12,067
		Rendering of utilities and other cost	Recurrent	-
		<b>Total</b>		<b>12,067</b>
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	5,861
		Rendering of medical services	Recurrent	62,863
		Rendering of utilities and other cost	Recurrent	67,850
		Purchases of Drugs and consumables	Recurrent	4,852
		Receiving of medical services	Recurrent	126,541
		Receiving of utilities and other cost	Recurrent	12,956
		<b>Total</b>		<b>280,924</b>
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	621
		Rendering of medical services	Recurrent	39,456
		Rendering of utilities and other cost	Recurrent	13,552
		Purchases of Drugs and consumables	Recurrent	427
		Receiving of medical services	Recurrent	16,450
		Receiving of utilities and other cost	Recurrent	876
		<b>Total</b>		<b>71,382</b>
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Receiving of utilities and other cost	Recurrent	-
		<b>Total</b>		<b>-</b>
Ceygen Biotech (Pvt) Ltd	Equity Accounted Investee	Purchases of Drugs and consumables	Recurrent	176,727
		Receiving of utilities and other cost	Recurrent	3,615
		<b>Total</b>		<b>180,341</b>
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Purchases of Drugs and consumables	Recurrent	21,532
		<b>Total</b>		<b>21,532</b>
Tudawe Brothers (Pvt) Ltd	Affiliate	Rendering of medical services	Recurrent	367
		<b>Total</b>		<b>367</b>
Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	20,869
		<b>Total</b>		<b>20,869</b>



**Share Information****Number of Shares Represented in Stated Capital**

Voting Shares	25,527,272
Non-Voting Shares	8,345,454
Total	<b>33,872,726</b>

**Public Shareholding as at 31st March 2021**

	<b>Voting</b>	<b>Non-Voting</b>
Number of shareholders	2,287	1,242
Number of shares	5,950,185	4,329,476
Holding Percentage	23.31%	51.88%
Float Adjusted Market Capitalisation (Rs Mn)	613	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

**Director's and Chief Executive Officer's Shareholding as at 31st March 2021**

	<b>Number of Shares</b>	
	<b>Voting</b>	<b>Non-Voting</b>
Mr A E Tudawe	215,052	-
Mr U D Tudawe	170,616	-
Dr A D P A Wijegoonewardene	220,582	-
Mr Y N R Piyasena	501,000	-
Mr A S Abeyewardene	1,440	1,200
Mr A S M Ismail	100	-
Mr A D B Talwatte	1,000	-
Mr. A.V.R. De Silva Jayatilleke	100	-
Mr. A.S. Tudawe	48	1,000

**Market Prices recorded during the Quarter**

	<b>Highest Traded Price</b>		<b>Lowest Traded Price</b>		<b>Last Traded Price</b>	
	<b>2021/22</b>	<b>2020/21</b>	<b>2021/22</b>	<b>2020/21</b>	<b>2021/22</b>	<b>2020/21</b>
	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>
Voting	<b>109.50</b>	93.80	<b>95.50</b>	75.00	<b>103.00</b>	80.40
	<b>19/05/2021</b>	<b>21/05/2020</b>	<b>27/04/2021</b>	<b>13/05/2020</b>	<b>30/06/2021</b>	<b>25/06/2020</b>
Non - Voting	<b>108.00</b>	77.00	<b>88.20</b>	67.10	<b>91.10</b>	70.40
	<b>18/05/2021</b>	<b>20/05/2020</b>	<b>09/04/2021</b>	<b>13/05/2020</b>	<b>30/06/2021</b>	<b>29/06/2020</b>

**Per Share Ratios**

	<b>Group</b>		<b>Company</b>	
	<b>As at</b>	<b>As at</b>	<b>As at</b>	<b>As at</b>
	<b>30/06/2021</b>	<b>30/06/2020</b>	<b>30/06/2021</b>	<b>30/06/2020</b>
	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>	<b>Rs</b>
Earnings Per Share	<b>5.72</b>	(0.61)	6.62	(1.43)
Net Asset Per Share	<b>198.19</b>	173.76	<b>152.14</b>	129.51

**Top 20 Shareholders Listed as at 30 June 2021****Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	17,437,146	68.31
Lawrance Tudawe Management Services (Pvt) Ltd	do	600,077	2.35
Mr Y N R Piyasena	do	501,000	1.96
Employee Provident Fund	do	437,330	1.71
Mr Deen Mohamed Fazal Aslam	do	410,000	1.61
Renuka Capital PLC	do	402,823	1.58
Mr. Merill J. Fernando	do	367,530	1.44
Mr. S. P. Tudawe (Deceased)	do	307,936	1.21
Cargo Boat Development Company PLC	do	305,485	1.20
MJF Holdings Ltd	do	270,981	1.06
Mr. A. D. P. A. Wijegoonewardene	do	220,582	0.86
Mr. A. E. Tudawe	do	215,052	0.84
Mrs H. K. Weerasinghe	do	200,000	0.78
Mrs L. I. Weerasinghe	do	200,000	0.78
Mrs T. T. Weerasinghe	do	200,000	0.78
Mr. U. D. Tudawe	do	170,616	0.67
Mr. A. D. Tudawe	do	161,984	0.63
Mr.A.H.Munasinghe	do	116,912	0.46
Mr. R. R. Tudawe	do	100,000	0.39
Commercial Bank of Ceylon PLC - A/C No.4	do	83,000	0.33
		<b>22,708,454</b>	<b>88.96</b>

**Non-Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	2,619,403	31.39
Employee Provident Fund	do	1,154,371	13.83
MJF Holdings Ltd	do	598,646	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	330,619	3.96
Mr. D. Ratnayake	do	146,866	1.76
Mr. A. H. Munasinghe	do	143,614	1.72
Tudawe Engineering Services (Pvt) Ltd	do	91,986	1.10
Mr. D. A. Cabraal	do	82,500	0.99
Mr. S. S. Sithambaranathan	do	75,650	0.91
Mr. P. S. De Mel	do	70,822	0.85
Mr. A. D. Tudawe	do	70,151	0.84
Mr. U. D. Wickremesooriya Jt. Mrs. S. F. Wickremesooriya	do	69,272	0.83
Ms. T. T. Weerasinghe	do	68,485	0.82
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	65,454	0.78
Commercial Bank of Ceylon PLC A/C No. 04	do	61,100	0.73
Mr. D. P. G. Dalpethado	do	59,494	0.71
Mr. D.P. L. De Mel	do	58,908	0.71
Saman Villas Limited	do	58,462	0.70
Mr. H A Cabraal	do	50,000	0.60
Hallsville Trading Group Inc	do	49,123	0.59
		<b>5,924,926</b>	<b>71.00</b>

## **CORPORATE INFORMATION**

### **Name of Company**

Ceylon Hospitals PLC

### **Brand Name**

DURDANS

### **Legal Form**

A quoted public company with limited liability  
incorporated in Sri Lanka under the Companies Ordinance  
No.51 of 1938 and registered under the Companies Act

### **Company Registration Number**

PQ 113

### **Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the  
Colombo Stock Exchange of Sri Lanka.

### **Registered Office**

No.03, Alfred Place, Colombo 03.

### **Bankers**

Bank of Ceylon  
Commercial Bank of Ceylon PLC  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
Sampath Bank PLC  
Seylan Bank PLC  
Union Bank PLC  
People's Bank

### **Auditors**

Messers.B.R.De.Silva & Co.  
Chartered Accountants  
No.22/4,Vijaya Kumaratunga Mawatha  
Colombo 05.

### **Lawyers**

Mr.D.F.R.Jayamaha  
Hector Jayamaha Law Office,  
No.228,Thimbirigasyaya Road,  
Colombo 05.

### **Secretaries**

Nexia Corporate  
Consultants (Pvt) Ltd  
No 181, Nawala road,  
Narahenpita.

### **Registrars**

S S P Corporate Services (Pvt) Ltd  
546, Galle Road,  
Colombo 03.